BTI 322

Drug Profile

BTI 322

Alternative Names: Anti-CD2 monoclonal antibody; Lo-CD2-a; Monoclonal antibody Lo-CD2-a

Latest Information Update: 21 Jun 2007

Price : $50

At a glance

  • Originator Catholic University of Louvain
  • Developer BioTransplant (CEASED); MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Graft-versus-host disease; Liver transplant rejection; Renal transplant rejection

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 12 Mar 2004 Discontinued - Phase-II for Renal transplant rejection in USA (IV)
  • 12 Mar 2004 Discontinued - Phase-II for Liver transplant rejection in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top